ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0322

Validation of NICE Criteria for the Diagnosis of Knee Osteoarthritis

Lauren King1, Ian Stanaitis2, Vivian Hung2, Sahil Koppikar3, Esther Waugh4, Lorraine Lipscombe3 and Gillian Hawker3, 1Women's College Hospital & St. Michael's Hospital & University of Toronto, Toronto, ON, Canada, 2Women's College Hospital, Toronto, ON, Canada, 3Women's College Hospital & University of Toronto, Toronto, ON, Canada, 4University of Toronto, Toronto, ON, Canada

Meeting: ACR Convergence 2023

Keywords: Diagnostic criteria, Osteoarthritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 12, 2023

Title: (0308–0324) Osteoarthritis – Clinical Poster I

Session Type: Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: The NICE guideline on osteoarthritis (OA) recommends that adults aged ≥45 should be diagnosed with OA clinically, without investigations, if they have activity-related joint pain and either no morning joint-related stiffness or morning stiffness that lasts no longer than 30 minutes. While the NICE criteria are frequently used and referenced as diagnostic criteria for OA, they have not been validated. The objective of this study was to validate the NICE criteria for knee OA. This was completed within the context of a larger project focused on identifying and treating OA in people with other chronic conditions.

Methods: This was a diagnostic test study. Reporting was guided by the SIGN checklist. We recruited participants with type 2 diabetes from endocrinology clinics at three academic hospitals in Toronto, Canada. We invited individuals aged ≥45 years with and without self-reported knee pain to participate (aiming for 50% with/without). We excluded individuals with a history of inflammatory rheumatic disease. Participants first self-completed a questionnaire to identify presence of activity-related knee pain and morning joint stiffness ≤30 min (NICE criteria for OA). As history and physical exam is considered the gold standard for making an OA diagnosis, an experienced rheumatologist, blinded to the questionnaire responses, conducted a standardized clinical assessment to identify presence of knee OA (yes, no, possible). A second rheumatologist completed a subset (n=11) of assessments in duplicate for validation of the rheumatologist’s assessment. We calculated the sensitivity (sens), specificity (spec), likelihood ratio positive (LR+) and likelihood ratio negative (LR-) of the NICE criteria to detect symptomatic knee OA (yes or possible).

Results: Our study included 91 participants with type 2 diabetes: mean age was 65.9 (SD 8.1) years, 50.6% women, mean BMI 29.1 (SD 6.6) kg/m2 (Table 1). 50 (54.9%) fulfilled the NICE criteria with a spectrum of illness severity: median (range) pain numeric rating score (0-10) was 5 (1-9). Gold standard assessment identified 51 (56.0%) participants with symptomatic knee OA (yes: n=48, possible [suspected to be early knee OA]: n=3). The sens, spec, LR+, and LR- of NICE criteria for symptomatic knee OA were 86.3%, 85.0%, 5.75, 0.16, respectively (Table 2). Activity-related knee OA (“Do you have pain or aching in one or both of your knee joints that comes on, or is made worse, by activities such as standing, walking, or climbing stairs”) alone, without combination with morning stiffness, improved operating characteristics (88.2%, 90.0%, 8.82, 0.12) (Table 3). There was high rheumatologist inter-rater reliability for OA diagnosis (kappa = 0.84).

Conclusion: The NICE criteria have high sensitivity and specificity for detecting symptomatic knee OA. A simplified version, assessing self-reported activity-related knee pain in individuals age ≥45 years, performed slightly better and may be a preferable OA diagnostic tool. This should be validated in other settings. Given purposeful recruiting, this study cannot assess positive and negative predictive values.

Supporting image 1

Table 1. Characteristics of participants (n=91)

Supporting image 2

Table 2. Accuracy of NICE criteria

Supporting image 3

Table 3. Accuracy of patient-reported activity-related knee pain (in individuals ≥45 years)


Disclosures: L. King: None; I. Stanaitis: None; V. Hung: None; S. Koppikar: None; E. Waugh: None; L. Lipscombe: Novo Nordisk, 5; G. Hawker: None.

To cite this abstract in AMA style:

King L, Stanaitis I, Hung V, Koppikar S, Waugh E, Lipscombe L, Hawker G. Validation of NICE Criteria for the Diagnosis of Knee Osteoarthritis [abstract]. Arthritis Rheumatol. 2023; 75 (suppl 9). https://acrabstracts.org/abstract/validation-of-nice-criteria-for-the-diagnosis-of-knee-osteoarthritis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2023

ACR Meeting Abstracts - https://acrabstracts.org/abstract/validation-of-nice-criteria-for-the-diagnosis-of-knee-osteoarthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology